risedronic acid has been researched along with Cholera Infantum in 20 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 9.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 5.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| " The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments." | 2.80 | The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. ( Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015) |
| "To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies." | 2.71 | Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. ( Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " The risk of an adverse upper GI event increases when these drugs are used concurrently with nonsteroidal anti-inflammatory drug (NSAID) therapy, but this incidence is no more than that observed with concurrent placebo and NSAID therapy." | 2.41 | Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. ( Baker, DE, 2002) |
| " Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects." | 2.41 | Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. ( Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| "The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice." | 1.32 | Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 13 (65.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Modi, A | 1 |
| Siris, ES | 1 |
| Steve Fan, CP | 1 |
| Sajjan, S | 1 |
| Gu, JM | 1 |
| Wang, L | 1 |
| Lin, H | 1 |
| Chen, DC | 1 |
| Tang, H | 1 |
| Jin, XL | 1 |
| Xia, WB | 1 |
| Hu, YQ | 1 |
| Fu, WZ | 1 |
| He, JW | 1 |
| Zhang, H | 1 |
| Wang, C | 1 |
| Yue, H | 1 |
| Hu, WW | 1 |
| Liu, YJ | 1 |
| Zhang, ZL | 1 |
| Cadarette, SM | 1 |
| Katz, JN | 1 |
| Brookhart, MA | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Levin, R | 1 |
| Solomon, DH | 1 |
| Blumentals, WA | 1 |
| Harris, ST | 1 |
| Cole, RE | 1 |
| Huang, L | 1 |
| Silverman, SL | 2 |
| Ralston, SH | 1 |
| Kou, TD | 1 |
| Wick-Urban, B | 1 |
| Steinbuch, M | 1 |
| Masud, T | 1 |
| Roux, C | 1 |
| Goldstein, JL | 1 |
| Zhou, X | 1 |
| Klemes, A | 1 |
| Lindsay, R | 2 |
| Chung, HY | 1 |
| Chin, SO | 1 |
| Kang, MI | 1 |
| Koh, JM | 1 |
| Moon, SH | 1 |
| Yoon, BK | 1 |
| Yoon, HK | 1 |
| Chung, YS | 1 |
| Park, HM | 1 |
| Landfeldt, E | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Ström, O | 1 |
| Baker, DE | 1 |
| Tremaine, WJ | 1 |
| Khosla, S | 1 |
| Hamilton, B | 1 |
| McCoy, K | 1 |
| Taggart, H | 2 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Adami, S | 3 |
| Pavelka, K | 1 |
| Cline, GA | 1 |
| Hosterman, MA | 1 |
| Barton, IP | 1 |
| Cohen, SB | 1 |
| Bensen, WG | 1 |
| Epstein, S | 1 |
| Delmas, PD | 1 |
| Emkey, R | 2 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Penning-van Beest, FJ | 1 |
| Goettsch, WG | 1 |
| Erkens, JA | 1 |
| Herings, RM | 1 |
| Strampel, W | 1 |
| Civitelli, R | 1 |
| Kishimoto, H | 1 |
| Miller, PD | 2 |
| Adachi, JD | 1 |
| Olszynski, WP | 1 |
| Kendler, DL | 1 |
| Licata, AA | 1 |
| Li, Z | 1 |
| Gomez-Panzani, E | 1 |
| Bolognese, MA | 1 |
| Ettinger, MP | 1 |
| Mulder, H | 1 |
| Josse, RG | 1 |
| Roberts, A | 1 |
| Zippel, H | 1 |
| Ernst, TF | 1 |
| Stevens, KP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836] | Phase 1 | 56 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for risedronic acid and Cholera Infantum
| Article | Year |
|---|---|
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem | 2012 |
Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Digestive System; Dr | 2002 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
The use of risedronate in Paget's disease.
Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia, | 1999 |
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clinical Trials, Phase III as | 2002 |
4 trials available for risedronic acid and Cholera Infantum
| Article | Year |
|---|---|
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; China; | 2015 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci | 2011 |
Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; D | 2005 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal | 2001 |
9 other studies available for risedronic acid and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Ga | 2015 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem | 2009 |
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, F | 2010 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal | 2002 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe | 2003 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr | 2006 |